UBS Maintains Buy Rating on Hansoh Pharmaceutical
UBS maintained its Buy rating on Hansoh Pharmaceutical.
Related stories
Consultant and Investment Group Reports Q3 Profit of 669,674 Dinars
M impact | EQUITY | Oct 29, 2026, 02:38 PM UTC
Howmet Executive Says Gas Turbine Capacity Is Sold Out Through 2031
Howmet's executive says major gas turbine customers report 2031 capacity is sold out; 2032 capacity will likely sell out in the next one or two quarters.
M impact | EQUITY | Oct 29, 2026, 02:37 PM UTC
IndiGo Says Fare Increases Inevitable as Fuel Costs Rise
IndiGo said fare increases are inevitable as fuel costs rise.
L impact | EQUITY | Oct 29, 2026, 02:37 PM UTC
Sanrio Apologizes, Scraps Japan TV Tie-Up After China Anger
Sanrio apologized after criticism in China and scrapped a Japan television tie-up, according to the headline.
L impact | EQUITY | Oct 29, 2026, 02:37 PM UTC
Restaurant Brands International Reports Mixed Quarterly Results
Restaurant Brands International reported mixed quarterly financial results. The report says consumer spending on discretionary items such as dining out remains weak.
M impact | EQUITY | Oct 29, 2026, 02:36 PM UTC
FERC Approves Rio Grande LNG Capacity Uprate; NextDecade Posts Quarterly Profit
NextDecade shares jumped after FERC approved a capacity uprate at the Rio Grande LNG project. The company also posted a quarterly profit.
M impact | EQUITY | Oct 29, 2026, 02:36 PM UTC